Log in or Sign up for Free to view tailored content for your specialty!
Juvenile Arthritis News
Etanercept, adalimumab improve wellbeing in non-systemic juvenile idiopathic arthritis
Etanercept and adalimumab are both impactful at improving the health of patients with non-systemic juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.
Kawasaki disease diagnoses fell one-third in Japan during first year of COVID pandemic
The number of patients diagnosed with Kawasaki disease in Japan fell by approximately one-third in 2020, with no indication that parents eschewed necessary hospital visits, according to data published in JAMA Pediatrics.
Log in or Sign up for Free to view tailored content for your specialty!
Genicular nerve block achieves 12-week improvement in juvenile idiopathic arthritis
In patients with juvenile idiopathic arthritis, genicular nerve block achieved “equivalent, longer-term improvement,” after 12 weeks compared with steroid therapy, according to data published in Clinical Rheumatology.
TNF inhibitor impacts, new ACR guidelines lead juvenile arthritis revelations
Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022.
AI model may help differentiate between MIS-C, Kawasaki disease
An artificial intelligence tool called KIDMATCH may be able to accurately distinguish between MIS-C, Kawasaki disease and other similar febrile diseases, according to data published in the Lancet Digital Health.
FDA approves Fresenius Kabi’s Idacio as eighth adalimumab biosimilar
The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.
JAK inhibition’s cardiovascular, malignancy risks are a ‘moving target’
PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.
Biologic, conventional DMARDs achieve better results in JIA when started together
PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic disease-modifying antirheumatic drug therapy concurrently had better results than patients on other plans, according to data presented here.
New model may help assess chronic uveitis risk in juvenile idiopathic arthritis
A validated prognostic tool using common clinical markers could help clinicians evaluate patients with juvenile idiopathic arthritis for chronic uveitis risk, according to data published in Arthritis & Rheumatology.
Groups highlight importance of physical activity on World Pediatric Bone and Joint Day
It is crucial that patients with juvenile arthritis stay active throughout their childhood for a better chance at building stronger bones, according to DMOS Orthopaedic Centers.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read